AngioDynamics Inc. (NASDAQ : ANGO) on Wednesday reported a third-quarter 2025 adjusted EPS of 3 cents, compared to the ...

The FDA accepts Apellis' sNDA seeking label expansion of Empaveli to treat two rare kidney diseases for review under the Priority Review pathway.

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...

Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of ...

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

Esteve will license the ex-U.S. rights for up to ten years and will also be receiving an option to acquire the international ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from ...

Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.

The current state of treatment for geographic atrophy is marked by two approved therapies that slow GA progression: ...

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 45.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company ...